Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial

被引：0
|
作者：
Yoshiteru Takekita
Yosuke Koshikawa
Chiara Fabbri
Shiho Sakai
Naotaka Sunada
Ai Onohara
Keiichiro Nishida
Masafumi Yoshimura
Masaki Kato
Alessandro Serretti
Toshihiko Kinoshita
机构：
[1] University of Bologna,Department of Biomedical and NeuroMotor Sciences
[2] Kansai Medical University,Department of Neuropsychiatry
来源：
BMC Psychiatry | / 16卷
关键词：
Schizophrenia; Risperidone long-acting injection; Paliperidone palmitate; Cognitive function; Efficacy; Subjective well-being;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study
    Miller, Brian J.
    Claxton, Amy
    Du, Yangchun
    Weiden, Peter J.
    Potkin, Steven G.
    SCHIZOPHRENIA RESEARCH, 2019, 208 : 44 - 48
  • [12] A randomized, double-blind study of paliperidone palmitate and risperidone long-acting therapy in schizophrenia
    Pandina, G.
    Lane, R.
    Gopal, S.
    Gassmann-Mayer, C.
    Hough, D.
    Remmerie, B.
    Simpson, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S481 - S482
  • [13] Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic
    Fleischhacker, WW
    Eerdekens, M
    Karcher, K
    Remington, G
    Llorca, PM
    Chrzanowski, W
    Martin, S
    Gefvert, O
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (10) : 1250 - 1257
  • [14] Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial
    Kim, Sung-Wan
    Chung, Young-Chul
    Lee, Yo-Han
    Lee, Jeong-Hoon
    Kim, Seon-Young
    Bae, Kyung-Yeol
    Kim, Jae-Min
    Shin, Il-Seon
    Yoon, Jin-Sang
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2012, 27 (05) : 267 - 274
  • [15] Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: A randomized, open-label, controlled trial
    Kim, S. -W.
    Chung, Y. -C.
    Lee, Y. -H.
    Lee, J. -H.
    Kim, S. -Y.
    Bae, K-Y.
    Jang, J. -E.
    Kim, J. -M.
    Shin, I. -S.
    Yoon, J. -S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 53 - 53
  • [16] Three-Year Outcomes of 6-Month Paliperidone Palmitate in Adults With SchizophreniaAn Open-Label Extension Study of a Randomized Clinical Trial
    Correll, Christoph U.
    Johnston, Karen
    Turkoz, Ibrahim
    Gray, Jason
    Sun, Liping
    Doring, Monica
    Sajatovic, Martha
    JAMA NETWORK OPEN, 2024, 7 (07) : e2421495
  • [17] Patient satisfaction with 6-month paliperidone palmitate versus other long-acting injectable antipsychotics
    Perez-Balaguer, A.
    Garcia del Castillo, I.
    Gomez-Esteban, B.
    Vicente-Burguillo, M.
    Vizcaino-Herrezuelo, H.
    Castelao-Almodovar, S.
    Arce de la Riva, A.
    Neira-Serrano, F.
    EUROPEAN PSYCHIATRY, 2024, 67 : S726 - S726
  • [18] Effects of switching to risperidone long-acting injection on cognitive function in schizophrenia
    Suzuki, H.
    Inoue, Y.
    Otomo, M.
    Kawaguchi, Y.
    Gen, K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S463 - S463
  • [19] Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
    Ascher-Svanum, Haya
    Montgomery, William S.
    McDonnell, David P.
    Coleman, Kristina A.
    Feldman, Peter D.
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2012, 5 : 391 - 398
  • [20] Effectiveness of paliperidone palmitate one-month long-acting injection in obese vs. non-obese patients
    Dorflinger, Charles
    LeHew, Colleen
    Carey, Heather
    Roche-Desilets, Jennifer
    Burant, Christopher J.
    COMPREHENSIVE PSYCHIATRY, 2021, 111
12345